top of page

ASGCT 2026: Rgenta Therapeutics has been developing oral small molecules to regulate RNA - after starting with endogenous targets, they realized they could do the same for transgene expression

  • 10 hours ago
  • 1 min read

Co-Founder and CEO Simon Xi discusses the company's Rswitch platform, which was the basis of an ASGCT presentation showing that the company could modulate levels of Frataxin in a Friedreich’s Ataxia mouse model.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page